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A recent Editorial1 described the potential for the evolution of SARS-CoV-2 variants that 18 
render vaccines less effective (vaccine escape), assisted by waning immunity following 19 
vaccination. This raises a crucial question: how can COVID-19 exit strategies be planned 20 
with only a low vaccine escape risk? 21 
 22 
A key component of any plausible strategy towards the permanent removal of non-23 
pharmaceutical interventions (NPIs) involves ensuring low case numbers in the short-to-24 
mid-term using NPIs and vaccination. Assuming a fixed vaccine escape mutation 25 
probability per infection (𝑝), the risk of a vaccine escape variant arising in a specified time 26 
period is  27 
Prob(vaccine escape) = 1 − (1 − 𝑝)𝑁 , 28 
where 𝑁 represents the number of cases in that period. 29 
 30 
Crucially, this indicates that the vaccine escape risk is sensitive to background incidence: 31 
the risk of an escape variant appearing within a fixed time is an increasing function of 32 
incidence (Fig 1). Reducing cases is not only beneficial for decreasing the pressure on 33 
healthcare systems, but also for lowering the vaccine escape risk. 34 
 35 
Of course, there are fundamental differences between using NPIs and vaccines to lower 36 
incidence. When considering vaccines that do not prevent transmission entirely, there is 37 
an interplay between reduced cases at the population-level and the potential for selection 38 
for vaccine escape variants in infected vaccinated hosts2–4. A related question is whether 39 
it is most beneficial to vaccinate many individuals using single vaccine doses or fewer 40 
individuals twice. “Dose-sparing” strategies could in theory lead to selection for vaccine 41 
escape variants5. However, current evidence suggests tentatively that the net vaccine 42 








Figure 1. The risk that at least one vaccine escape 51 
variant arises in a time period of length t, for 52 
different daily numbers of cases. In this figure, the 53 
per infection probability of vaccine escape is 𝑝 =54 






Despite its simplicity, our quantitative illustration demonstrates that strategies for 61 
mitigating the vaccine escape risk should be explored. Reducing case numbers locally 62 
should only be one component of these strategies. Travel restrictions to reduce the risk 63 
of importing novel variants should be considered. We recognise that assessing the 64 
escape variant emergence risk not only requires the variant to arise via mutation as 65 
considered here, but also to grow to appreciable frequencies. This is a stochastic process, 66 
depending on the availability of hosts to infect and the escape variant’s fitness. A 67 
reduction in cases leads to both a reduction in the risk of escape variants appearing and 68 
a reduction in their subsequent establishment through transmission around the 69 
population. Acquisition of additional mutations that are beneficial for the virus is also more 70 
likely to be suppressed if incidence rates are reduced. 71 
 72 
In summary, high SARS-CoV-2 incidence rates act to increase the vaccine escape risk. 73 
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